Background The first national recommendations on neuraxial anaesthesia and
antithrombotic drugs were published by the German Society for Anaesthesiology and …

Managing patients in the perioperative setting receiving novel oral anticoagulation agents
for thromboprophylaxis or stroke prevention with atrial fibrillation is an important …

New direct oral anticoagulant agents (DOAC) are currently licensed for thromboprophylaxis
after hip and knee arthroplasty and for longterm prevention of thromboembolic events in non …

The current mainstay of treatment of thrombotic APS is long-term anticoagulation with oral
vitamin K antagonists (VKA) such as warfarin. However, the use of warfarin is problematic …

The widespread use of central neuraxial block (CNB) and the prevalence of anticoagulation
for different indications have led to an inevitable overlap between the two. The most serious …

The field of oral anticoagulation has evolved with the arrival of non‐vitamin K antagonist oral
anticoagulants (NOACs) including an anti‐IIa agent (dabigatran etexilate) and anti‐Xa …

A number of novel anticoagulants are moving through various stages of drug development.
Recently, the United States Food and Drug Administration approved the oral direct thrombin …

New oral anticoagulants (NOACs) are increasingly replacing standard anticoagulants.
These new drugs have been recently introduced in clinical practice, and specific knowledge …

Introduction: For over 50 years, vitamin K antagonists such as warfarin (Aldocumar®) and
acenocoumarol (Sintrom®) have been the gold standard for reducing the risk of …

Dabigatran etexilate (DE), rivaroxaban, and apixaban are nonvitamin K antagonist oral
anticoagulants (NOACs) that have been compared in clinical trials with existing …